










































Erratum to 'The management of chronic hepatitis B in the
immunocompromised patient: recommendations from a single
topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254]
Citation for published version:
Barclay, S, Pol, S, Mutimer, D, Benhamou, Y, Mills, PR, Hayes, PC, Cameron, S & Carman, W 2008,
'Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: recommendations
from a single topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254]' Journal of Clinical Virology, vol 42, no. 1,
pp. 104-15.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Journal of Clinical Virology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Journal of Clinical Virology 42 (2008) 104–115
Meeting report
Erratum to ‘The management of chronic hepatitis B in the
immunocompromised patient: Recommendations
from a single topic meeting’
[J. Clin. Virol. 41 (4) 2008 243–254]
Stephen Barclay a,∗, Stanislas Pol b, David Mutimer c, Yves Benhamou d,
Peter R. Mills a, Peter C. Hayes e, Sheila Cameron f, William Carman f
a Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom
b Liver Unit and Inserm U-567, Hoˆpital Cochin, Paris, France
c Queen Elizabeth Hospital, Birmingham, United Kingdom
d Grp Hosp Pitie Salpetriere, Paris, France
e Scottish Liver Transplant Unit, Edinburgh Royal Inﬁrmary, Edinburgh, United Kingdom
f West of Scotland Specialist Virology Centre, Gartnavel General Hospital, Glasgow, United Kingdom
Abstract
Patients with chronic hepatitis B virus (HBV) infection have a substantial risk of reactivation and jaundice following the use of immuno-
suppressant therapy. A single topic conference was convened to discuss the management of HBV patients undergoing chemotherapy for
haematological malignancy, liver and renal transplantation and with HIV co-infection. In advance of the meeting a draft guideline was pre-
pared and circulated to a participating expert panel. Presentations and consensus views were obtained on the day of conference to allow
pragmatic algorithms to be established on each of these topics.
Use of lamivudine prophylaxis for HBV patients undergoing chemotherapy and renal transplantation is strongly supported with good
evidence. Patients with HBV cirrhosis who are candidates for transplantation should be started on nucleos(t)ide therapy prior to surgery
and, in addition, hepatitis B immune globulin given from the time of transplantation onward. Co-infection with HBV and HIV offers unique
challenges. If the patient is a candidate for highly active retroviral therapy then dual nucleos(t)ide analogues which are also active against
HBV must be used to prevent immune reconstitution hepatitis. In all these conditions, awareness of possible HBV resistance to therapy must
be kept in mind and HBV DNA levels monitored.
Keywords: Hepatitis B; Immunocompromised host; HIV; Kidney transplantation; Liver transplantation; Chemotherapy
1. Introduction
The management of chronic hepatitis B virus (HBV) infec-
tion in immunocompromised patients presents challenges
above and beyond those routinely encountered in this already
complex disease. With this in mind a single topic conference
was convened jointly, in May 2007 by the Scottish Viral Hep-
atitis Group and the Scottish Diagnostic Virology Group to
DOIs of original articles:10.1016/j.jcv.2007.11.017,
10.1016/j.jcv.2008.03.020
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discuss the management of hepatitis B in the specific con-
texts of chemotherapy for haematological malignancy, liver
and renal transplantation and HIV co-infection.
2. Methods and aims
The aim of the meeting was to generate pragmatic guide-
lines combining best available evidence and expert opinion.
In advance of the meeting a discussion document containing
draft guidelines was prepared and circulated to a participat-
ing expert panel. On the day of the meeting presentations
1386-6532/$ – see front matter
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were given on each of the topics followed by a panel dis-
cussion with questions from the floor. The discussions were
transcribed and used to prepare the following guidelines
which are presented in Figs. 1–4, and discussed here in
turn.
2.1. Management of hepatitis B infection in patients
undergoing chemotherapy for haematological
malignancy (Fig. 1)
2.1.1. Background
Chemotherapy induced reactivation of hepatitis B is a
well-recognised phenomenon first described over 30 years
ago (Galbraith et al., 1975). It is thought that chemotherapy-
induced immunosuppression allows a rapid increase in viral
replication (Mindikoglu et al., 2006). Between cycles, or after
cessation of chemotherapy, reconstitution of the immune sys-
tem takes place. During this period a T cell-mediated immune
response may occur against the increased number of infected
hepatocytes with a clinical picture ranging from elevation of
ALT, through jaundice, fulminant liver failure and death (Lok
et al., 1991).
Whilst no uniform definition of reactivation exists one that
is commonly used is the presence of hepatitis (as suggested
by an ALT > 3ULN) in combination with either a 10-fold rise
in HBV DNA viral load or an absolute value greater than
20,000 IU/ml. The risk of reactivation for HBsAg-positive
patients undergoing chemotherapy for haematological malig-
nancy is between 33% and 67% (Lok et al., 1991; Nakamura
et al., 1996; Markovic et al., 1999; Yeo et al., 2005), with
regimes containing high dose steroid or rituximab indepen-
dently increasing risk (Cheng, 1996; Takai et al., 2005;
Hui et al., 2006). Patient factors conferring increased risk
include high serum HBV DNA pre-chemotherapy (Lau et
al., 2002; Yeo et al., 2004), male sex and high levels of
ALT.
Reactivation mortality rates have been reported variously
as between 5% and 37% (Lok et al., 1991; Nakamura et al.,
1996; Markovic et al., 1999), with more patients developing
jaundice. The latter causes significant morbidity and may
necessitate interruption of chemotherapy potentially leading
to a poorer treatment outcome.
Although less common, reactivation may occur in patients
who are HBsAg negative but positive for other markers of
prior exposure to the virus, including anti-HBc or anti-HBs
alone or in combination (Lok et al., 1991; Law et al., 2005;
Hui et al., 2006). Although the reactivation rate is lower
amongst this group, in the region of 5%, reactivation carries a
significant risk of mortality and morbidity (Hui et al., 2006).
In areas of low HBV endemicity up to 20% of patients with
markers of prior exposure to HBV will have anti-HBc in iso-
lation, which may represent acute infection, occult infection,
resolved distant infection or a false positive result (Grob et al.,
2000). Those with occult HBV infection, defined as HBsAg
negative with low-level detectable HBV DNA, appear to have
the greatest risk (Hui et al., 2006).
2.1.2. Screening of patients undergoing chemotherapy
Given the high rate of reactivation and subsequent mor-
bidity/mortality amongst patients with chronic hepatitis B
undergoing chemotherapy it is recommended that all patients
undergoing chemotherapy for haematological malignancies
have their HBV status assessed by testing for serum HBsAg
and anti-HBc. The rate of HBV infection may be higher
amongst patients with haematological malignancy than in the
background population (Pioltelli et al., 2000; Kim et al., 2002;
Talamini et al., 2004; Marcucci et al., 2006) and screening is
cheap and widely available.
2.1.3. Evaluation of HBsAg-positive patients
HBsAg-positive patients should have their serum HBV
DNA levels checked. Those patients with HBV DNA lev-
els >2000 IU/ml should be evaluated further with regards to
serum ALT, e-antigen status, liver biopsy or non-invasive
markers of fibrosis (Myers et al., 2003), and considered as
potential candidates for treatment rather than prophylaxis.
These patients are at highest risk of reactivation on with-
drawal of prophylaxis (Lau et al., 2002; Yeo et al., 2004) and
indefinite therapy may be required.
2.1.4. Prevention of reactivation
Prophylaxis strategies against hepatitis B reactivation
have concentrated on the nucleoside analogue lamivudine,
with less published data concerning newer nucleos(t)ide
analogues. Interferon- is unlikely to be tolerated in
patients undergoing chemotherapy due to its side effect pro-
file.
Good evidence exists that pre-emptive (started before
chemotherapy introduced) lamivudine prophylaxis prevents
reactivation of hepatitis B in HBsAg-positive patients under-
going chemotherapy, with a systematic review identifying
a reduction in reactivation rates of between four and sev-
enfold (Kohrt et al., 2006). The same analyses found
excellent tolerability and safety of lamivudine in patients
undergoing chemotherapy, with no significant adverse drug
effects.
The available data suggests prophylaxis is superior to
delaying treatment until serological evidence of reactivation
is detected (Lau et al., 2003) and it is therefore recommend
that all HBsAg-positive patients undergoing chemotherapy
receive nucleoside analogue prophylaxis. Whilst lamivudine
has the largest body of evidence in the setting, newer ana-
logues such as adefovir and entecavir are likely to be equally
effective. Given the improved resistance profile of such drugs,
it is likely that as experience with such drugs grows, they will
succeed lamivudine as first line prophylactic therapy in this
setting.
2.1.5. HBsAg-negative patients with markers of HBV
infection
As HBsAg-negative patients are at lower risk of reacti-
vation different strategies have been advocated to avoid the
need for universal prophylaxis. The most promising of these
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Fig. 1. Algorithm for the prevention of reactivation of hepatitis B infection in patients undergoing chemotherapy for haematological malignancy.
is the use of sensitive HBV DNA assays to identify those
with isolated anti-HBc that have occult infection. Unfortu-
nately at risk patients will often have DNA levels of less
than 100 copies/ml, and in some cases DNA will only be
detectable by nested PCR techniques (Hui et al., 2006). As
the assays required for such a strategy are largely unavail-
able in routine practice it was not felt that such an approach
could be routinely recommended. In future this may become
the preferred option, and institutions with current access to
adequately sensitive assays may wish to pursue such a strat-
egy.
A strategy of fortnightly HBV DNA estimations and insti-
gation of prophylaxis only in the event of a 100-fold rise
in DNA (Hui et al., 2006) could not be recommended due
to several issues. These include unproven cost effectiveness,
difficulties ensuring adequate supervision of patients outwith
a clinical trial setting, and a lack of a prospective trial to
establish that such an approach is effective both in prevent-
ing adverse outcome and reducing the number of patients
requiring prophylaxis.
Other recommendations have included vaccination of iso-
lated anti-HBc-positive patients with a single dose of HBV
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vaccine to induce anti-HBs, and to exclude those patients
with an antibody response from prophylaxis (Lalazar et al.,
2007). It is known that, at least in HBV naı¨ve patients, vac-
cine is less effective in those with haematological malignancy
(Weitberg et al., 1985; Goyal et al., 1998) and in the absence
of a prospective trial of such an approach it is unclear how
many patients would avoid prophylaxis. Given this, together
with evidence that anti-HBs is not uniformly protective of
reactivation (Hui et al., 2006) it was not felt that such an
approach could be recommended.
Given the excellent safety profile of lamivudine in the
context of chemotherapy it is felt that any risks of unnec-
essary treatment are outweighed by the benefits of ensuring
all at risk patients are treated. Equally it is important that
any guideline does not introduce undue delay or confusion
into a situations were timely treatment is of the essence. It
was therefore agreed that nucleoside analogue prophylaxis
be given to all HBsAg-negative patients who are anti-HBc-
positive, although in time wider availability of more sensitive
assays may more readily identify those truly at risk.
2.1.6. Duration of prophylaxis
Prophylaxis is recommended to start 7 days prior to com-
mencing chemotherapy and to continue for 6 months after
cessation of chemotherapy, although both figures are arbi-
trary and further work is required on the optimal duration of
treatment. Patients should have their ALT monitored every
4 weeks during prophylaxis, with HBsAg and HBV DNA
testing every 3 months or if serum ALT is elevated. As in
other settings a greater than 10-fold rise in HBV DNA above
the nadir should trigger testing for resistance to lamivudine
or other prescribed nucleos(t)ide. Due to a risk of recurrence
after withdrawal of prophylaxis, monitoring should continue
for 1 year after cessation of therapy.
2.1.7. Non-haematological malignancy and patients
with chronic inﬂammatory conditions
Although published experience is more limited, HBV
reactivation is recognised amongst patients undergoing
chemotherapy for non-haematological malignancy. Yeo et al.
(2004) reported reactivation rates varying between 6.9% for
gastrointestinal cancers and 41% for breast carcinoma. The
authors reported an increased risk amongst patients receiving
anthracyclines and steroids (both commonly used in the treat-
ment of haematological malignancies), suggesting that the
degree of immunosuppression induced may be more impor-
tant than the underlying malignancy. Therefore, decisions
regarding prophylaxis for solid organ tumours should be indi-
vidualised, based on the proposed chemotherapy regimen.
Amongst patients receiving immunosuppression for
chronic inflammatory conditions, such as rheumatoid arthri-
tis and inflammatory bowel disease, reports of reactivation
of hepatitis B are increasingly recognised. Agents implicated
include both traditional treatments such as methotrexate and
corticosteroids, and the newer anti-TNF biological agents
(Esteve et al., 2004; Calabrese et al., 2006). These case reports
include several deaths resulting from hepatic failure, and
whilst the absolute risk remains unclear, nucleos(t)ide ana-
logue prophylaxis should be considered in HBsAg-positive
patients commencing such therapy, with close monitoring of
any patients not receiving prophylaxis.
2.2. Hepatitis B and liver transplantation (Fig. 2)
2.2.1. Background
Prior to the introduction of hepatitis B immunoglobulin
(HBIg) liver transplantation (LT) in patients with hepatitis B
was associated with a high rate of graft re-infection, which in
the context of immunosuppression led to rapidly progressive
liver disease (Todo et al., 1991; Samuel et al., 1993). Mor-
tality in the pre-HBIg era was high with a 5-year survival
rate of between 40% and 60% (Todo et al., 1991; Samuel et
al., 1993). With the introduction of HBIg monotherapy and
subsequently combination therapy with HBIg and lamivu-
dine, graft re-infection rates were dramatically reduced and
outcomes for HBV infected patients began to match or even
exceed other transplant indications (Kim et al., 2004).
2.2.2. Management of HBV cirrhosis prior to
transplantation
Patients with HBV DNA titres in excess of 2000 IU/ml are
at increased risk of disease progression (Iloeje et al., 2006)
and hepatocellular carcinoma (HCC) (Chen et al., 2006).
Likewise suppression of viral replication may lead to an
improvement in liver function and survival and in some cases
obviate the need for transplantation (Perrillo et al., 2001).
The panel agreed that it would be unusual for a patient
to come to transplantation without antecedent indication for
antiviral therapy. The need for transplantation defined the pre-
ceding level of replication as harmful. It was therefore agreed
that patients being listed for transplantation with detectable
HBV DNA by commercial PCR assays should be commenced
on antiviral therapy. Agreed principles of selecting antiviral
therapy were to maximally suppress replication and ensure
ongoing viral susceptibility at the time of transplantation to
the agent(s) chosen. To ensure this, patients should undergo
repeat DNA testing every 3 months in order to screen for
emerging antiviral resistance.
2.2.3. Prevention of recurrence post-transplant
Early strategies to prevent graft re-infection used human
immunoglobulin with high titres of antibody to HBsAg
(known as HBIg). Factors shown to be associated with failure
of HBIg prophylaxis included transplantation for cirrhosis
(compared with fulminant infection), HBe-antigen positivity
and high HBV DNA levels. Those with delta virus co-
infection appeared to have a low risk (Samuel et al., 1993).
The use of high dose HBIg (to maintain titres >500 IU/ml)
reduced the risk of recurrence to between 15% and 35%
(McGory et al., 1996; Terrault et al., 1996).
Initially the nucleoside analogue lamivudine was used as
monoprophylaxis against graft re-infection. Whilst effective
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in the short term, over time high rates of antiviral resistance
were observed and emergence of resistant virus was asso-
ciated with significant graft infection and damage (Lok et
al., 2003). With the availability of antiviral therapy which is
effective against lamivudine-resistant strains, some centres
have adopted a strategy of sequential use of antivirals to man-
age the problem of lamivudine resistance (Lo et al., 2007). A
recent analysis suggested that whilst such a strategy may be
cost effective, this is at the risk of increased recurrence and
mortality rates (Dan et al., 2006).
The use of both HBIg and lamivudine in combination has
led to HBV recurrence rates of less than 10% (Angus et al.,
2000; Marzano et al., 2001; Rosenau et al., 2001) and this
is now considered the standard of care. A wide variety of
HBIg regimes are in successful use and these vary in dosage,
routes of administration (intravenous (Markowitz et al., 1998;
Han et al., 2000; Marzano et al., 2001; Rosenau et al., 2001;
Roche et al., 2003) versus low dose intramuscular (Yao et al.,
1999; Yoshida et al., 1999; Angus et al., 2000; Zheng et al.,
2006; Gane et al., 2007)), and dosing schedules (fixed dos-
ing (Markowitz et al., 1998; McCaughan et al., 1999; Yao et
al., 1999; Angus et al., 2000; Han et al., 2000; Marzano et
al., 2001; Zheng et al., 2006; Gane et al., 2007) versus on-
demand (Yoshida et al., 1999; Rosenau et al., 2001; Roche
et al., 2003)). Until recently the longest published follow-up
data existed for intravenous regimes, with median follow-up
Fig. 2. Algorithm for the management of hepatitis B in patients undergoing liver transplantation.
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periods of 30 months and 5 years in the studies by Marzano
et al. (2001) and Roche et al. (2003) demonstrating recur-
rence rates of only 3.8% and 8%, respectively. However, more
recently Gane et al. (2007) published results of a cohort of 147
patients from Australia and New Zealand who received either
400 IU/month or 800 IU/month intramuscularly in whom the
actuarial risk of recurrence at 5 years was 4%.
Adefovir has also been used in an open label compassion-
ate use study for patients with lamivudine-resistant virus both
pre- and post-transplant (Schiff et al., 2007). Amongst the 57
patients coming to transplant HBV recurrence was low with
HBsAg detectable on first assay in 6% and 9% of patients
who did or did not receive HBIg, respectively. Serum HBV
DNA was detected on consecutive visits in 6% and 0% of
patients who did or did not receive HBIg, respectively. The
authors concluded that adefovir was successful in preventing
HBV recurrence in lamivudine-resistant patients regardless
of whether HBIg was co-administered, though the study was
not designed to compare the differing regimes and follow up
was short. At present a multicentre UK trial is underway
to establish if adefovir can be substituted for HBIg post-
transplant in high-risk patients. Data for HBIg in combination
with other nucleos(t)ide analogues is limited but studies using
newer analogues, such as entecavir, to prevent recurrence in
the post-transplant patient are ongoing.
Reflecting the best evidence for preventing recurrence
the authors recommend the combination of HBIg and a
nucleos(t)ide analogue to which virus is susceptible to pre-
vent post-transplant recurrence. It is thought likely that in
future combination nucleos(t)ide therapy may supplant the
use of HBIg.
2.2.4. Withdrawal of HBIg
Issues of cost, availability and patient factors such as toler-
ability and convenience of administration have led to attempts
to identify strategies to allow safe withdrawal of HBIg ther-
apy with continued prophylaxis with a nucleos(t)ide(s) alone.
The strategies most commonly pursued have been either to
identify those at lowest risk of recurrence, or to vaccinate
patients to induce host production of anti-HBs.
Those at low risk of recurrence of HBV include patients
transplanted for fulminant hepatic failure and those with low
HBV DNA levels prior to instigation of antiviral therapy
(Samuel et al., 1993; Gane et al., 2007). Long-term follow-
up of 20 patients who had withdrawal of HBIg between 1
and 18 months post-transplant found recurrence in 4 (18%)
patients, however, 3 of these cases were felt to relate to poor
compliance with therapy (Buti et al., 2006). More recently
Wong et al. (2007) reported a retrospective analysis of 21
patients, 3 of whom received 1 week only of HBIg and
the remainder a median of 20 months. At a median of 42
months (range 4.5–51) following withdrawal of HBIg only
one patient (4.8%) had recurrence.
Attempts to induce anti-HBs titres by vaccination have had
varied success. Various measures to enhance host response to
vaccine have been attempted, however, comparing differing
approaches is difficult due to differences in the viral status
of patients, immunosuppressive regimes used and the levels
of anti-HBs defined as response. In addition differences in
co-administration of lamivudine or HBIg during vaccination
have been used to explain differing response rates between
otherwise similar studies. The most impressive results using
standard recombinant vaccine by Sanchez-Fueyo et al. (2000)
have not been replicated (Angelico et al., 2002; Di et al.,
2006), whilst third generation recombinant vaccines contain-
ing additional pre-S1 and pre-S2 gene products have given
mixed results (Karasu et al., 2005; Lo et al., 2007). The most
promising results thus far have been those reported by Bienzle
et al. (2003), who used a novel adjuvant system to achieve
anti-HBs titres of >500 IU/ml in 16/20 (80%) of patients.
Further studies, varying the adjuvant used, have proved less
successful and further trials are required (Starkel et al., 2005;
Rosenau et al., 2006).
It is the authors view that patients at high risk of recur-
rence should always be maintained on combination antiviral
therapy, and that the most robust evidence exists for HBIg in
combination with a nucleos(t)ide analogue. Patients at low
risk of recurrence, that is those transplanted for fulminant
hepatic failure or with low pre-treatment DNA levels, should
be considered for HBIg withdrawal after a period of com-
bination prophylaxis, but should be monitored carefully for
HBsAg and DNA relapse after HBIg withdrawal. Vaccina-
tion can be considered for patients in whom withdrawal is
planned, however the optimal vaccine has yet to be identified
and decisions about vaccination should be independent of the
decision to withdraw HBIg.
2.3. Management of hepatitis B in patients undergoing
renal transplantation (Fig. 3)
2.3.1. Background
The incidence of HBV infection in patients coming to
renal transplantation continues to fall as a result of immuni-
sation of pre-dialysis and dialysis patients, regular screening
for infection and strict infection control measures (Finelli et
al., 2005). Despite these measures the prevalence in devel-
oped countries is still between 0% and 8% (Burdick et al.,
2003). Hepatitis B infection in patients with end stage renal
disease (ESRD) is usually asymptomatic even in the acute
period and typically up to 80% of patients’ progress to a
chronic carrier state (Harnett et al., 1988).
2.3.2. Effects of HBV infection on outcome
The influence of HBsAg-positive infection on outcome
following renal transplant has been controversial. However
a meta-analysis of published trials in 2005 concluded a sig-
nificantly higher all cause mortality (relative risk 2.49, 95%
CI 1.64–3.78) and risk of graft failure (relative risk 1.4, 95%
CI 1.02–2.04) (Fabrizi et al., 2005). Most, but not all of the
studies, concluded significantly higher risk of death from liver
cirrhosis or hepatocellular carcinoma.
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Fig. 3. Algorithm for the management of hepatitis B in patients undergoing renal transplantation.
Mathurin et al. (1999) found a 10-year survival rate of
45% amongst HBsAg-positive patients comparing poorly
with both HCV infected patients (65%) and a case matched
control population without evidence of HBV or HCV infec-
tion (80%). In patients who had a biopsy proven diagnosis of
cirrhosis, 10-year survival was as low as 26%.
The largest study to undertake serial liver biopsies in
patients positive for HBsAg after renal transplant found histo-
logical deterioration in 85.3% of patients, including cirrhosis
in 28% at a mean interval of 66 months, no patients having
been cirrhotic on baseline biopsy (Fornairon et al., 1996).
Amongst those patients with cirrhosis, HCC was found in
23%, suggesting an annual incidence of HCC of between
2.5% and 5%.
2.3.3. Reactivation in HBsAg-negative patients
The risk of reactivation of HBV amongst patients with
previously “resolved” infection, that is negative for HBsAg
and positive for anti-HBc, is low. Berger et al. (2005) found
recurrence (reappearance of HBsAg) in 2/229 (0.9%) of such
patients, 1 of whom was asymptomatic. Knoll et al. (2005)
presented data looking at recurrence amongst kidney, liver
and heart transplant recipients all of whom where HBsAg-
negative and anti-HBc-positive pre-transplant. Of 23 such
patients receiving a renal transplant only 1 patient (4.3%)
developed transient recurrence of HBsAg. More recently
Savas et al. (2007) reported two cases of reactivation and
provided a review of 25 previously reported cases. They
noted a wide age range of patients experiencing recurrence
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(22–75 years), a male preponderance and a time of onset
post-transplant of between 8 weeks and 15 years. The authors
noted that with one exception all patients had anti-HBs titres
of less than 100 IU/ml and suggest that vaccination of such
patients may be an effective preventative measure. No trials
evaluating such an approach were identified.
2.3.4. Assessment prior to transplant
Virtually all patients being assessed will have their HBsAg
status previously documented and will have undergone vac-
cination if negative.
Assessment of HBsAg-positive patients with ESRD is
complicated by a number of issues. Serum transaminase lev-
els are lower than in non-uraemic populations with the normal
cut off for ALT being estimated as low as 17 IU/l (Hung
et al., 1997). Whilst dialysis patients with positive HBsAg
are likely to have higher ALT values than those who are
negative (Fabrizi et al., 2002), transaminase levels may not
equate with histological findings (Rodrigues et al., 1997). In
addition HBV DNA measurements are less well validated in
patients with ESRD. Fabrizi et al. (2003) demonstrated that
whilst HBsAg-positive patients with detectable HBV DNA
had significantly higher levels of ALT than those who were
negative (mean 19 IU/ml versus 12 IU/ml), overall DNA lev-
els were low (mean 4.09 × 102 copies/ml) and the correlation
with disease progression remains uncertain.
Serological markers of fibrosis such as the commercially
available Fibrotest panel have been evaluated in ESRD and
transplant patients with similar efficacy to other populations
and may remove the need for liver biopsy in approximately 1
in 3 patients (Imbert-Bismut et al., 2001; Varaut et al., 2005).
Theoretically non-invasive tests using transient elastography
may be less accurate in uraemic patients due to increased
skin stiffness, but data is limited. Given the uncertainties
surrounding interpretation of transaminase and HBV DNA
levels liver biopsy is often required to assess the severity of
liver disease.
It was the view of the panel that with the advent of potent
antiviral therapy, cirrhosis in itself should no longer be con-
sidered a contraindication to renal transplantation. However,
patients with decompensated liver disease should however
continue to be assessed for combined liver and renal trans-
plantation.
2.3.5. Management post-transplant—antiviral therapy
The evidence for using interferon alpha post renal trans-
plant is limited but available data suggest a high associated
risk of graft rejection, precluding its use (Durlik et al.,
1995). Likewise issues regarding efficacy and tolerability
limit its use in ESRD patients being considered for transplant
(Rodrigues et al., 1997).
The largest body of evidence in the renal transplant set-
ting is for lamivudine with a meta-analysis by Fabrizi et al.
(2004) demonstrating rates of HBV DNA and HBe-antigen
clearance of 91% and 72%, respectively. Resistance rates
across the trials were significant at 18% after median treat-
ment duration of 18 months. Studies evaluating the benefits
of prophylactic lamivudine versus treatment only on reacti-
vation suggest that with the latter approach the majority of
patients will end up on treatment (Chan et al., 2002) and may
have a worse outcome than those treated prophylactically
(Filik et al., 2006).
Limited data is available regarding use of the newer
antivirals in renal transplant patients. One small study by
Fontaine et al. (2005) suggests that adefovir, is safe and as
effective as in non-transplanted patients. Like adefovir and
lamivudine, entecavir requires dose adjustment according to
creatinine clearance. No data regarding its use in renal trans-
plant patients was identified.
Given the high risks of reactivation and disease progres-
sion amongst HBsAg-positive patients it was the view of
the meeting that all such patients should be treated with
antiviral therapy and as in other situations the choice of this
should reflect the goals of maximally suppressing viral repli-
cation and minimising resistance. It was suggested that in
the absence of other indications for treatment patients under-
going live donor transplantation should commence antiviral
prophylaxis 4–6 weeks prior to transplantation and that in
cadaveric organ recipients treatment may be deferred until
the time of transplant.
Given the low risk of reactivation of patients who are
HBsAg negative it is not recommended that universal pro-
phylaxis is given. Limited evidence suggests that amongst
those positive for anti-HBc, those with low titres of anti-
HBs (<100 IU/ml) are at greatest risk and repeat vaccination
should be considered for this group. Amongst those with iso-
lated anti-HBc-positive serology sensitive HBV DNA assays
may detect those with true occult infection. However data on




As in other settings monitoring for treatment failure and
the development of resistance is crucial and initially this
should be performed every 3–4 months. Closer observation of
the patient should be considered during changes in immuno-
suppression which may precipitate reactivation. The panel
were of the opinion that nucleos(t)ide analogue prophylaxis
should be considered in HBsAg-negative/anti-HBc-positive
patients during periods of escalation of immunosuppression,
for example the treatment of rejection.
2.4. Hepatitis B and HIV co-infection (Fig. 4)
2.4.1. Background
Approximately 9% of HIV-infected patients in Europe
have co-infection with hepatitis B (Konopnicki et al., 2005).
It might have been expected that HIV-related immune dys-
function would lead to a more benign course of liver disease
in those patients with co-infection. However the evidence is
that co-infection leads to a more aggressive course of liver
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Fig. 4. Algorithm for the management of hepatitis B in patients co-infected with HIV.
disease (Puoti et al., 2006), with patients demonstrating both
higher liver related and all cause mortality compared to those
with HIV mono-infection (Thio et al., 2002; Konopnicki et
al., 2005).
Excellent management guidelines for HBV/HIV co-
infection exist including those resulting from a 2004
consensus conference held in North America (Soriano et al.,
2005), the 1st European consensus on the treatment of chronic
hepatitis B and C in HIV co-infected patients (Benhamou,
2006) and the British HIV association guidelines on co-
infection with HIV and hepatitis B virus infection (Brook
et al., 2005), to which we would direct the reader. We pro-
vide a brief summary on HIV co-infection and a treatment
algorithm is presented in Fig. 4.
2.4.2. Assessment of HBV status
As in the mono-infected patient HBV assessment includes
measurement of ALT, e-antigen status and HBV DNA levels.
Serum ALT levels are lower than in mono-infected patients,
however, this does not necessarily correlate with hepatic
inflammation and therefore ALT is less useful in predict-
ing significant liver disease (Colin et al., 1999). Likewise
the significance of DNA levels in co-infected patients is less
well defined and guidelines tend to follow those for mono-
infected patients. These difficulties mean that liver biopsy is
often required to assess need for treatment. Non-invasive tests
for hepatic fibrosis, either biochemical or using elastography,
may be considered but have yet to be fully validated in the
co-infectedpatient.
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2.4.3. Treatment
Appropriate treatment is dependent on whether there are
indications to treat HBV, HIV or both. In each of these situa-
tions the guiding principle is to minimise viral resistance by
avoiding regimes that contain only one agent effective against
a particular virus. In addition to the antivirals licensed for
HBV mono-infection, the nucleos(t)ide analogues tenofovir
and emtricitabine, which are licensed for HIV infection, are
also effective against HBV (Ristig et al., 2002; Gish et al.,
2005; Lim et al., 2006; Benhamou et al., 2006a).
For patients requiring treatment of both HBV and HIV a
HAART regime including two agents with anti-HBV activ-
ity should be used, typically involving tenofovir with either
lamivudine or emtricitabine. Regimes that include single
agents active against HBV, in particular those with poor resis-
tance profiles such as lamivudine or emtricitabine should be
avoided.
Amongst those patients with an indication for HIV ther-
apy alone, those with high HBV DNA levels (>2000 IU/ml)
require treatment regimes as above in order to minimise the
risk of an immune reconstitution hepatitis. Those with DNA
levels <2000 IU/ml and no other indication for treatment, for
example cirrhosis, do not need regimes with dual activity but
should have regular monitoring of viral status. It is important
that increased consideration be given to the patients HBV
status prior to changes being made to a HAART regime, in
particular where a nucleos(t)ide with anti-HBV activity is
due to be withdrawn.
For those patients with an indication for treatment of HBV
alone the options are somewhat limited, although in the panels
experience such patients are relatively uncommon. Adefovir
at a dose of 10 mg daily has been shown to be effective
in co-infected patients and does not induce HIV resistance
mutations (Delaugerre et al., 2002; Benhamou et al., 2006b).
Initial evidence for entecavir’s effectiveness in co-infected
patients has been tempered by evidence of induction of HIV
resistance mutations (Colono et al., 2006; McMahon et al.,
2007). For those patients who are e-antigen positive then
pegylated interferon alpha can be considered. The evidence
for interferon alpha relates to non-pegylated preparations in
trials predating the widespread use of HAART (Wong et al.,
1993). These suggested decreased effectiveness compared to
its use in mono-infected patients and further studies in the
context of current HIV therapy are required.
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